Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2025)

Revolution Medicines has reported Total Non-Current Liabilities over the past 7 years, most recently at $704.7 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $704.7 million for Q4 2025, up 140.97% from a year ago — trailing twelve months through Dec 2025 was $704.7 million (up 140.97% YoY), and the annual figure for FY2025 was $704.7 million, up 140.97%.
  • Total Non-Current Liabilities for Q4 2025 was $704.7 million at Revolution Medicines, up from $649.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for RVMD hit a ceiling of $704.7 million in Q4 2025 and a floor of $87.6 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $144.9 million (2022), compared with a mean of $231.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 8.31% in 2023 and later soared 232.78% in 2025.
  • Revolution Medicines' Total Non-Current Liabilities stood at $134.8 million in 2021, then decreased by 6.19% to $126.4 million in 2022, then skyrocketed by 85.11% to $234.1 million in 2023, then rose by 24.94% to $292.4 million in 2024, then soared by 140.97% to $704.7 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $704.7 million (Q4 2025), $649.1 million (Q3 2025), and $558.9 million (Q2 2025) per Business Quant data.